Release of platelet-activating factor in systemic lupus erythematosus1

C. Tetta, F. Bussolino, V. Modena, G. Montrucchio, G. Segoloni, G. Pescarmona, G. Camussi

Research output: Contribution to journalArticle

Abstract

The biologically active l-0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet-activating factor; PAF) is inactivated in plasma mainly by a specific PAF acetylhydrolase (l-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine acetylhydrolase; EC 3.1.1.48). In the present study, PAF was released in detectable amounts (5.4 ±2.9 ng/ml; mean± 1 SD) in the plasma of 8 out of 10 patients with systemic lupus erythematosus (SLE) during the most active phases of the disease. PAF was never detectable in the plasma of patients with inactive SLE or of healthy subjects. PAF acetylhydrolase activity was markedly reduced in sera of 10 patients with active SLE as compared to 7 patients with inactive SLE, 16 patients with rheumatoid arthritis (RA), 5 patients with nephrotic syndrome (NS) and 15 healthy subjects. A kinetic study of the enzyme in patients with active SLE suggested an overall reduced activity rather than an intrinsic defect of the enzyme. PAF acetylhydrolase in sera of patients with active SLE shared with that of healthy subjects the same substrate specificity, sensitivity to enzymatic and chemicophysical treatments and association to low-density lipoprotein (LDL), acting as carrier of PAF acetylhydrolase in plasma. However, the protein concentration of LDL was significantly reduced in patients with active SLE as compared to patients with inactive SLE, RA and NS and to healthy subjects, thereby suggesting that the reduction of PAF acetylhydrolase activity in active SLE might be due at least in part to a carrier defect related to the activity of the disease. In addition, experiments in which serum of patients with active SLE and serum of healthy subjects were mixed in different combinations indicated the absence of factors inhibiting PAF acetylhydrolase activity in SLE patients.

Original languageEnglish
Pages (from-to)244-256
Number of pages13
JournalInternational Archives of Allergy and Immunology
Volume91
Issue number3
DOIs
Publication statusPublished - 1990

Fingerprint

Platelet Activating Factor
Systemic Lupus Erythematosus
1-Alkyl-2-acetylglycerophosphocholine Esterase
Healthy Volunteers
Phosphorylcholine
Nephrotic Syndrome
Serum
LDL Lipoproteins
Rheumatoid Arthritis
Enzymes
Substrate Specificity

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Tetta, C., Bussolino, F., Modena, V., Montrucchio, G., Segoloni, G., Pescarmona, G., & Camussi, G. (1990). Release of platelet-activating factor in systemic lupus erythematosus1. International Archives of Allergy and Immunology, 91(3), 244-256. https://doi.org/10.1159/000235124

Release of platelet-activating factor in systemic lupus erythematosus1. / Tetta, C.; Bussolino, F.; Modena, V.; Montrucchio, G.; Segoloni, G.; Pescarmona, G.; Camussi, G.

In: International Archives of Allergy and Immunology, Vol. 91, No. 3, 1990, p. 244-256.

Research output: Contribution to journalArticle

Tetta, C, Bussolino, F, Modena, V, Montrucchio, G, Segoloni, G, Pescarmona, G & Camussi, G 1990, 'Release of platelet-activating factor in systemic lupus erythematosus1', International Archives of Allergy and Immunology, vol. 91, no. 3, pp. 244-256. https://doi.org/10.1159/000235124
Tetta, C. ; Bussolino, F. ; Modena, V. ; Montrucchio, G. ; Segoloni, G. ; Pescarmona, G. ; Camussi, G. / Release of platelet-activating factor in systemic lupus erythematosus1. In: International Archives of Allergy and Immunology. 1990 ; Vol. 91, No. 3. pp. 244-256.
@article{e45cec33b7ed4781bb0e4b71fa9d8698,
title = "Release of platelet-activating factor in systemic lupus erythematosus1",
abstract = "The biologically active l-0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet-activating factor; PAF) is inactivated in plasma mainly by a specific PAF acetylhydrolase (l-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine acetylhydrolase; EC 3.1.1.48). In the present study, PAF was released in detectable amounts (5.4 ±2.9 ng/ml; mean± 1 SD) in the plasma of 8 out of 10 patients with systemic lupus erythematosus (SLE) during the most active phases of the disease. PAF was never detectable in the plasma of patients with inactive SLE or of healthy subjects. PAF acetylhydrolase activity was markedly reduced in sera of 10 patients with active SLE as compared to 7 patients with inactive SLE, 16 patients with rheumatoid arthritis (RA), 5 patients with nephrotic syndrome (NS) and 15 healthy subjects. A kinetic study of the enzyme in patients with active SLE suggested an overall reduced activity rather than an intrinsic defect of the enzyme. PAF acetylhydrolase in sera of patients with active SLE shared with that of healthy subjects the same substrate specificity, sensitivity to enzymatic and chemicophysical treatments and association to low-density lipoprotein (LDL), acting as carrier of PAF acetylhydrolase in plasma. However, the protein concentration of LDL was significantly reduced in patients with active SLE as compared to patients with inactive SLE, RA and NS and to healthy subjects, thereby suggesting that the reduction of PAF acetylhydrolase activity in active SLE might be due at least in part to a carrier defect related to the activity of the disease. In addition, experiments in which serum of patients with active SLE and serum of healthy subjects were mixed in different combinations indicated the absence of factors inhibiting PAF acetylhydrolase activity in SLE patients.",
author = "C. Tetta and F. Bussolino and V. Modena and G. Montrucchio and G. Segoloni and G. Pescarmona and G. Camussi",
year = "1990",
doi = "10.1159/000235124",
language = "English",
volume = "91",
pages = "244--256",
journal = "International Archives of Allergy and Immunology",
issn = "1018-2438",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Release of platelet-activating factor in systemic lupus erythematosus1

AU - Tetta, C.

AU - Bussolino, F.

AU - Modena, V.

AU - Montrucchio, G.

AU - Segoloni, G.

AU - Pescarmona, G.

AU - Camussi, G.

PY - 1990

Y1 - 1990

N2 - The biologically active l-0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet-activating factor; PAF) is inactivated in plasma mainly by a specific PAF acetylhydrolase (l-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine acetylhydrolase; EC 3.1.1.48). In the present study, PAF was released in detectable amounts (5.4 ±2.9 ng/ml; mean± 1 SD) in the plasma of 8 out of 10 patients with systemic lupus erythematosus (SLE) during the most active phases of the disease. PAF was never detectable in the plasma of patients with inactive SLE or of healthy subjects. PAF acetylhydrolase activity was markedly reduced in sera of 10 patients with active SLE as compared to 7 patients with inactive SLE, 16 patients with rheumatoid arthritis (RA), 5 patients with nephrotic syndrome (NS) and 15 healthy subjects. A kinetic study of the enzyme in patients with active SLE suggested an overall reduced activity rather than an intrinsic defect of the enzyme. PAF acetylhydrolase in sera of patients with active SLE shared with that of healthy subjects the same substrate specificity, sensitivity to enzymatic and chemicophysical treatments and association to low-density lipoprotein (LDL), acting as carrier of PAF acetylhydrolase in plasma. However, the protein concentration of LDL was significantly reduced in patients with active SLE as compared to patients with inactive SLE, RA and NS and to healthy subjects, thereby suggesting that the reduction of PAF acetylhydrolase activity in active SLE might be due at least in part to a carrier defect related to the activity of the disease. In addition, experiments in which serum of patients with active SLE and serum of healthy subjects were mixed in different combinations indicated the absence of factors inhibiting PAF acetylhydrolase activity in SLE patients.

AB - The biologically active l-0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet-activating factor; PAF) is inactivated in plasma mainly by a specific PAF acetylhydrolase (l-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine acetylhydrolase; EC 3.1.1.48). In the present study, PAF was released in detectable amounts (5.4 ±2.9 ng/ml; mean± 1 SD) in the plasma of 8 out of 10 patients with systemic lupus erythematosus (SLE) during the most active phases of the disease. PAF was never detectable in the plasma of patients with inactive SLE or of healthy subjects. PAF acetylhydrolase activity was markedly reduced in sera of 10 patients with active SLE as compared to 7 patients with inactive SLE, 16 patients with rheumatoid arthritis (RA), 5 patients with nephrotic syndrome (NS) and 15 healthy subjects. A kinetic study of the enzyme in patients with active SLE suggested an overall reduced activity rather than an intrinsic defect of the enzyme. PAF acetylhydrolase in sera of patients with active SLE shared with that of healthy subjects the same substrate specificity, sensitivity to enzymatic and chemicophysical treatments and association to low-density lipoprotein (LDL), acting as carrier of PAF acetylhydrolase in plasma. However, the protein concentration of LDL was significantly reduced in patients with active SLE as compared to patients with inactive SLE, RA and NS and to healthy subjects, thereby suggesting that the reduction of PAF acetylhydrolase activity in active SLE might be due at least in part to a carrier defect related to the activity of the disease. In addition, experiments in which serum of patients with active SLE and serum of healthy subjects were mixed in different combinations indicated the absence of factors inhibiting PAF acetylhydrolase activity in SLE patients.

UR - http://www.scopus.com/inward/record.url?scp=0025352277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025352277&partnerID=8YFLogxK

U2 - 10.1159/000235124

DO - 10.1159/000235124

M3 - Article

C2 - 2354868

AN - SCOPUS:0025352277

VL - 91

SP - 244

EP - 256

JO - International Archives of Allergy and Immunology

JF - International Archives of Allergy and Immunology

SN - 1018-2438

IS - 3

ER -